Cardinal Health (CAH) Stock
Major US distributor of pharmaceuticals and medical supplies. Here's the price, business snapshot, and what's worth knowing about Cardinal Health in November 2026.
Cardinal Health, Inc. (CAH) is a major US healthcare services and products company, with a market capitalisation near $37.7 billion. It operates large-scale pharmaceutical distribution and supplies medical-surgical products to hospitals, pharmacies and clinics, while also developing higher‑margin device and services offerings. Investors should know the business combines high-volume, low-margin distribution with targeted growth in medical products, so operational efficiency, inventory management and contract terms are key profit levers. The company faces sector-specific risks including reimbursement pressure, hospital budget cycles, regulatory scrutiny and strong competition from peers. Recent strategic emphasis has been on margin improvement, specialty products and supply-chain resilience, though execution and healthcare demand trends will matter. This is general educational information, not personalised advice; values can rise or fall and past performance is no guarantee of future results. Consider how exposure to healthcare distribution fits your risk tolerance and investment horizon before acting.
Why It’s Moving
Cardinal Health Beats Q1 Estimates and Raises Outlook, Defying Market Volatility
- Quarterly non-GAAP EPS of $3.26 beat the consensus estimate of $2.92, reflecting a 28% year-over-year increase fueled by specialty growth and generics demand.
- Revenue rose 5% to $67.5 billion, with management raising the fiscal 2027 non-GAAP EPS guidance to a range of $12.80–$13.00, signaling confidence in sustained operational strength.
- The company completed a $500 million share repurchase program during the quarter, reinforcing capital return strategies while offsetting pressures in its medical distribution segment.
Cardinal Health Beats Q1 Estimates and Raises Outlook, Defying Market Volatility
- Quarterly non-GAAP EPS of $3.26 beat the consensus estimate of $2.92, reflecting a 28% year-over-year increase fueled by specialty growth and generics demand.
- Revenue rose 5% to $67.5 billion, with management raising the fiscal 2027 non-GAAP EPS guidance to a range of $12.80–$13.00, signaling confidence in sustained operational strength.
- The company completed a $500 million share repurchase program during the quarter, reinforcing capital return strategies while offsetting pressures in its medical distribution segment.
Sixth Month Growth Performance
When is the next earnings date for CARDINAL HEALTH INC (CAH)?
Cardinal Health has not yet confirmed a specific date for its next earnings release. Based on the company's historical reporting pattern, which typically follows a quarterly cycle of approximately three months after the previous report, the upcoming announcement is expected in February 2027. This future report will likely cover the fiscal fourth quarter and full-year results for the period ending December 31, 2026. Investors should monitor official communications for the precise scheduling details as they become available.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cardinal Health's stock, expecting it to rise toward a target price of $213.89.
Financial Health
Cardinal Health is generating substantial revenue but has low profitability and cash flow metrics.
Dividend
Cardinal Health's low dividend yield of 0.76% may not attract income-focused investors. If you invested $1000 you would be paid $7.60 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Scale & Distribution
A wide distribution network underpins revenue through volume, but margins are typically thin so operational efficiency is essential.
Higher‑Margin Push
Growth in medical devices and services aims to lift margins, though execution risk and competitor response are important considerations.
Regulation & Cycles
Reimbursement trends, hospital spending cycles and regulatory changes can materially affect performance, and returns may vary over time.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
